Rare disease drugmaker · part of Sanofi · based in Cambridge, United States · founded 2011 · blueprintmedicines.com
Blueprint Medicines works on 3 rare diseases we track, including Gastrointestinal Stromal Tumor, Mastocytosis and 1 more. It has 7 active clinical trials, and 6 are looking for volunteers now. It also has 1 FDA-approved rare disease drug.
Blueprint Medicines is a precision therapy company focused on genomically defined cancers and blood disorders. Sanofi completed its $9.1 billion acquisition of Blueprint on July 18, 2025 (announced June 2025). The lead product is avapritinib (Ayvakit/Ayvakyt), approved for advanced systemic mastocytosis, indolent systemic mastocytosis (ISM, approved 2023), and PDGFRA D842V-mutant gastrointestinal stromal tumors.
Blueprint Medicines pipeline
Each row lists the diseases Blueprint Medicines is studying at that stage, from the ones closest to approval down to the earliest work.
These are Blueprint Medicines trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
6 trials looking for volunteers now
Looking for volunteersRecently updatedNCT07143669
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM.
The study is designed to follow each participant up to a maximum of 24 months.
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with ISM.
This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a concern. In this study, investigators aim to study the safety and tolerability of combined avapritinib and decitabine for the treatment of SM-AHN.
Underway, not taking new volunteersPhase 2Recently updatedNCT03731260
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.
Follow a condition Blueprint Medicines is studying
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Blueprint Medicines. Unsubscribe anytime.
You'll get, for Gastrointestinal Stromal Tumor:
Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
Blueprint also discovered pralsetinib (Gavreto) for RET-altered cancers. Roche returned its rights in 2024, and Blueprint sold the U.S. rights to Rigel Pharmaceuticals the same year. The pipeline includes elenestinib (BLU-263), a next-generation KIT D816V inhibitor in Phase 2/3 for indolent systemic mastocytosis.
Where Blueprint Medicines trials take place
The trials above run at 200 study sites in 26 countries. Tap a country to see its states, cities and hospitals.
United States
73▼
Germany
28▼
Italy
14▼
France
13▼
United Kingdom
10▼
Belgium
8▼
Netherlands
7▼
Spain
6▼
Canada
4▼
Portugal
4▼
Sweden
4▼
Norway
3▼
Rare diseases Blueprint Medicines works on
Each disease page lists every open trial, not only Blueprint Medicines's, plus approved treatments.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors.
How common: About 6,000 new cases per year in the U.S. (American Cancer Society); true incidence may be higher as small GISTs are often incidentally discovered
Systemic Mastocytosis is a rare hematologic disorder characterized by accumulation and proliferation of abnormal mast cells in bone marrow, lymphoid tissues, and other organs.
How common: Approximately 1 case per 10,000 to 20,000 people; can occur at any age but more common in adults
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Blueprint Medicines's own site is blueprintmedicines.com, and our help paying for treatment page lists drugmaker programs and charity funds.
1 shared disease, including Gastrointestinal Stromal Tumor
Questions about Blueprint Medicines
Blueprint Medicines is a precision therapy company focused on genomically defined cancers and blood disorders. Sanofi completed its $9.1 billion acquisition of Blueprint on July 18, 2025 (announced June 2025). The lead product is avapritinib (Ayvakit/Ayvakyt), approved for advanced systemic mastocytosis, indolent systemic mastocytosis (ISM, approved 2023), and PDGFRA D842V-mutant gastrointestinal stromal tumors. Blueprint also discovered pralsetinib (Gavreto) for RET-altered cancers. Roche returned its rights in 2024, and Blueprint sold the U.S. rights to Rigel Pharmaceuticals the same year. The pipeline includes elenestinib (BLU-263), a next-generation KIT D816V inhibitor in Phase 2/3 for indolent systemic mastocytosis.
Blueprint Medicines has active programs across 3 rare diseases: Gastrointestinal Stromal Tumor, Mastocytosis, Systemic Mastocytosis. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
Yes, mainly. Blueprint Medicines is a rare disease specialist headquartered in Cambridge, United States, founded in 2011. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Gastrointestinal Stromal Tumor, Mastocytosis, Systemic Mastocytosis. It operates as part of Sanofi.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Blueprint Medicines, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
Blueprint Medicines has 1 FDA-approved drug with a rare disease use that we track, as of November 2026.
Source: the FDA's openFDA label database, matched to the rare diseases on Trial Friend; the list updates automatically and can include older products.
Yes, for 1 of its FDA-approved rare disease medicine that we track, each checked on Blueprint Medicines' own website.
Ayvakit: YourBlueprint, 1-888-258-7768. Offers copay help with private insurance, a free medicine program, a short-term supply while insurance is decided and insurance help. Checked October 12, 2026.
Medicare and Medicaid: drugmaker copay cards are limited to private insurance, so people with government coverage usually look to a free medicine program or a charity fund, both on the help paying page.
Eligibility is decided by each program, so call the number listed before a prescription is filled.
Blueprint Medicines was founded in 2011 and is headquartered in Cambridge, United States. The company has been active for 15 years. It is a subsidiary of Sanofi. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.